SUMMARY
This study sought to determine whether the sodium/glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved heart failure (HF) outcomes in nondiabetic mice. The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial demonstrated that empagliflozin markedly prevented HF and cardiovascular death in subjects with diabetes. However, despite ongoing clinical trials in HF patients without type 2 diabetes, there are no objective and translational data to support an effect of SGLT2 inhibitors on cardiac structure and function, particularly in the absence of diabetes and in the setting of established HF. Male C57Bl/6 mice were subjected to either sham or transverse aortic constriction surgery to induce HF. Following surgery, mice that progressed to HF received either vehicle or empagliflozin for 2 weeks.
Cardiac function was then assessed in vivo using echocardiography and ex vivo using isolated working hearts.
Although vehicle-treated HF mice experienced a progressive worsening of cardiac function over the 2-week treatment period, this decline was blunted in empagliflozin-treated HF mice. Treatment allocation to empagliflozin resulted in an improvement in cardiac systolic function, with no significant changes in cardiac remodeling or diastolic dysfunction. Moreover, isolated hearts from HF mice treated with empagliflozin displayed significantly improved ex vivo cardiac function compared to those in vehicle-treated controls. Empagliflozin treatment of nondiabetic mice with established HF blunts the decline in cardiac function both in vivo and ex vivo, independent of diabetes. These data provide important basic and translational clues to support the evaluation of SGLT2 inhibitors as a treatment strategy in a broad range of patients with established HF. trial demonstrated that the sodium/glucose cotransporter 2 (SGLT2) inhibitor empagliflozin markedly reduced cardiovascular death and heart failure hospitalization in subjects with type 2 diabetes (1).
Despite the profound and precocious efficacy, the physiological and biomolecular mechanisms responsible for this w40% reduction in cardiovascular mortality and heart failure are not known. Interestingly, intrinsic changes to the cardiac tissue itself have largely been ruled out because SGLT2 receptors are not known to be present in the heart (2). Based in part on this fact, the prevailing theories explaining how empagliflozin may exert its beneficial effects in heart failure involve either improved hemodynamics through osmotic diuresis and natriuresis (3) or by promoting enhanced ketone oxidation by the heart through increased ketone concentrations in the blood (3). However, these theories have not been fully investigated. In addition, because empagliflozin is used to treat diabetes, it is not known whether the drug is capable of eliciting equally beneficial effects on heart failure outcomes in nondiabetic patients. 
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A U G U S T 2 0 1 7 : 3 4 7 -5 4 connected to a mouse ventilator (MiniVent; Harvard Apparatus, Holliston, Massachusetts). Following midline sternotomy, a double-blunted 27-gauge needle was tied encircling the aorta between the innominate and left common carotid arteries using a 6/0 silk suture. The needle was then removed, and chest and skin were sutured and closed.
ECHOCARDIOGRAPHY. Mice were anesthetized with 1.0% to 1.5% isoflurane with 1 to 1.5 l/min 100% oxygen, and in vivo cardiac function was assessed by transthoracic echocardiography using a Vevo 3100 high-resolution imaging system equipped with a Comparisons between groups were performed using Mann-Whitney U test (E) and repeated measures 2-way ANOVA followed by Sidak multiple comparisons tests (F). **p < 0.01 versus baseline. Empa ¼ empagliflozin; HF ¼ heart failure; TAC ¼ transverse aortic constriction.
Byrne et al.
A U G U S T 2 0 1 7 : 3 4 7 -5 4
Empagliflozin Prevents Worsening of Cardiac Function following 2-week oral gavage of vehicle or empagliflozin.
HISTOLOGY. Masson's trichrome and hematoxylineosin stains of paraffin-embedded left ventricular heart sections taken mid-papillary were visualized using microscopy (DMLA microscope, Leica Microsystems, Wetzlar, Germany; equipped with a Retiga 1300i FAST 1394 charge-coupled device camera, OImaging, Surrey, British Columbia, Canada), as described previously (6) . Three representative images were taken of each sample.
EX VIVO HEART PERFUSIONS. Hearts were perfused in the working heart mode at 11.5 mm Hg preload and 50 mm Hg afterload with Krebs-Henseleit buffer containing 0.8 mmol/l oleate prebound to 3% delipidated bovine serum albumin, 5 mmol/l glucose, and 50 mU/ml insulin, as described previously (4,7).
STATISTICS. Results are expressed as mean AE SEM. Statistical analyses were performed using Prism software (GraphPad Corp., La Jolla, California).
Comparisons between groups were performed by Wilcoxon signed-rank test, Mann-Whitney U test, or repeated measures 2-way ANOVA, followed by Sidak multiple comparisons test where appropriate. Wilcoxon signed rank test was used to evaluate preversus post-gavage data (Figure 1) . A p value of <0.05 was considered significant.
RESULTS
In order to help address the effects of empagliflozin in heart failure in the absence of diabetes, we subjected healthy C57Bl/6 mice to TAC surgery to induce heart failure as described previously (7) . Following TAC surgery, mice were subjected to pulsed wave Doppler M-mode echocardiography. Mice demonstrating an EF of <45% were subsequently randomized and treated with either vehicle (0.5% hydroxyethyl cellulose) or empagliflozin (10 mg/kg) by daily oral gavage for a period of 2 weeks ( Figure 1A) . As expected, empagliflozin significantly increased glucose concentrations in the urine during the treatment period ( Figure 1B) . In addition, whereas vehicletreated mice with heart failure continued to display a significant drop in %EF over the 2-week treatment 
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A U G U S T 2 0 1 7 : 3 4 7 -5 4 period ( Figures 1C, 1E , and 1F), empagliflozin-treated mice maintained stable cardiac function ( Figures 1D   to 1F ). In order to account for dependent data, a repeated measures 2-way ANOVA was used to show that a statistically significant interaction existed between the effect of time and treatment on %EF In addition to development of cardiac hypertrophy, we also measured indices of diastolic function such as LV filling pressure (E/E 0 ratio) ( Figure 3A ) and the mitral E/A ratio ( Figure 3B ), which were also not 
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Empagliflozin Prevents Worsening of Cardiac Function significantly changed between groups. Furthermore, because excessive myocardial fibrosis is a major result of pressure overload-induced heart failure (8,9), we used Masson trichrome staining to investigate whether treatment with empagliflozin reduced cardiac collagen content. Consistent with our observation that empagliflozin did not reduce myocardial stiffness, there was no obvious reduction in cardiac fibrosis compared to vehicle-treated mice with heart failure ( Figure 3C ). Furthermore, we also investigated the presence of macrophage infiltration in hearts from vehicle-and empagliflozin-treated mice with heart failure to assess the effect of empagliflozin on the inflammatory response to pressure overload.
Interestingly, there was no obvious presence of macrophage infiltration in either group ( Figure 3D) , suggesting that the inflammatory response to pressure overload had likely resolved prior to when the mice were euthanized and hearts used for histology.
To ascertain whether or not the protective effects observed in the empagliflozin-treated mice with heart failure were related to extrinsic factors that controlled cardiac function (such as hemodynamics or ketone oxidation), we subjected vehicle-and empagliflozin-treated mice to ex vivo functional assessment using an isolated perfused working heart system (7). In the presence of matching pre-load and after-load pressures, identical concentrations of insulin, fatty acids, and glucose, as well as in the absence of ketones (7), ex vivo perfused hearts still demonstrated significantly improved ex vivo cardiac output ( Figure 4A ) and cardiac work ( Figure 4B ), without any differences in heart rate ( Figure 4C ).
This ability of empagliflozin to provide a sustained benefit in isolated hearts suggests that the empagliflozin-mediated prevention of worsening cardiac function in mice with heart failure may be due to an intrinsic and sustained cardiac effect and is not based on potential hemodynamic changes or a potentially confounding blood-based environmental milieu associated with heart failure and other factors related to empagliflozin treatment.
DISCUSSION
Together, our data show for the first time that empagliflozin treatment of nondiabetic mice with reduced EF heart failure blunts the progressive decline in cardiac function both in vivo and ex vivo.
Interestingly, although SGLT1 mRNA is abundantly expressed in the human heart as well as in other tissues, SGLT2, the selective target of empagliflozin, has been identified in skeletal muscle and kidney but not in heart (10, 11) . Thus, our findings introduce a completely novel concept that empagliflozin can directly influence cardiac function despite no definitive evidence of molecular targets in cardiac tissue. Interestingly, numerous studies propose that empagliflozin may reduce cardiometabolic risk in diabetic Hearts from vehicle-and Empa-treated mice with HF were perfused ex vivo to measure cardiac function. Cardiac output (A), cardiac work (B), and heart rate (C) were measured using ex vivo perfused working hearts (n ¼ 9 to 10). Results are mean AE SEM. Abbreviations as in Figure 1 .
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A U G U S T 2 0 1 7 : 3 4 7 -5 4 patients by significantly reducing body weight and adiposity (17, 18) ; however, no changes in body weight were found in our study. Although it has also been suggested that the glucose-lowering effects of empagliflozin may reduce the cardiac effects of glucotoxicity (19, 20) , our data suggest that empagliflozin has cardioprotective benefits even in the absence of elevated blood glucose. Furthermore, despite previous findings that empagliflozin mildly reduces cardiac hypertrophy, improves diastolic function, and reduces collagen deposition in female mice with diabetes and obesity (21), these improvements were not apparent in our study using a mouse model of heart failure without impaired glucose handling.
STUDY LIMITATIONS. Although it was not measured in the current study, the effect of empagliflozin on the abnormal ventricular electrophysiological profile exists in cardiac hypertrophy and failure (22) (23) (24) (25) may offer insight into the mechanism of action and would therefore be an area to explore in future studies.
Furthermore, although we observed increased cardiac function both in vivo and ex vivo, another limitation of our study is that we do not know whether empagliflozin improves cardiomyocyte contractility, which could provide additional insight into potential mechanism of action.
CONCLUSIONS
Although there are no data for biomarkers in patients with heart failure treated with SGLT2 inhibitors, preliminary data suggest that SGLT2 inhibition can reduce atrial natriuretic peptide and B-type natriuretic peptide in zebrafish models of heart failure (26) and improve measurements of diastolic function in humans with diabetes and clinical cardiovascular disease (27 
